Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
new york blog main
11
×
new york top stories
boston top stories
clinical trials
national top stories
biotech
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
drugs
new york
novartis
alirocumab
alnylam pharmaceuticals
bristol-myers squibb
cancer
eli lilly
evolocumab
fremanezumab
What
drug
11
×
new
11
×
fda
approved
approval
cholesterol
medicine
medicines
bio
brings
class
companies
data
disease
drugs
gets
known
looms
lowering
medco
migraine
nash
nod
oks
patients
roundup
tough
wave
won
acorda
acquire
advantages
agreed
alnylam
amgen
arguments
bar
based
big
billion
Language
unset
Current search:
drug
×
new
×
" new york blog main "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines